Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in
the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma …

Representing the major cause of morbidity and mortality for chronic lymphocytic leukemia
(CLL) patients, immunosuppression is a common feature of the disease. Effectors of the …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, which is associated with
profound alterations and defects in the immune system and a prevalent dependency on the …

Background: B-cell receptor (BCR) signaling is crucial for normal B-cell development and
adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display …

Chronic lymphocytic leukemia (CLL) is a malignancy of mature, antigen-experienced B
lymphocytes. Despite great progress recently achieved in the management of CLL, the …

Chronic lymphocytic leukemia (CLL) is associated with substantial alterations in T-cell
composition and function. However, the role of T-cells in CLL remains largely controversial …

B cells play an essential role in adaptive immunity and are intimately correlated with
pleiotropic immune-mediated diseases. Each B cell occupies a unique B cell receptor …

B-cell receptor (BCR) signaling and tumor–microenvironment crosstalk both drive chronic
lymphocytic leukemia (CLL) pathogenesis. Within the microenvironment, tumor cells shape …

Chronic lymphocytic leukemia (CLL) major stereotyped subset 2 (IGHV3-21/IGLV3-21,∼
2.5% of all cases of CLL) is an aggressive disease variant, irrespective of the somatic …

ABSTRACT Introduction Randomized clinical trials (RCTs) have suggested that BTK
inhibitors (BTKis) might increase infectious disease (ID) risk. Systematic analysis of this topic …